Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026

About this email

Captured October 28, 2026Announcement

Novo Nordisk announces new clinical and real-world data across Wegovy and investigational efruxifermin for MASH at The Liver Meeting 2026.

Basic text-heavy press release layout with brand logo at top, followed by bulleted highlights, multi-paragraph corporate statements, session agendas, and contact listings.

Color palette

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.

More emails like this

Explore other emails with shared design, campaign, or industry tags.

Reuters

Netanyahu survives another day

Create this for my brand

GGovDocs

Your Compliance Questions, Answered: Voting Leave, Updates to Okla.’s Medical Marijuana Law, and Calif.’s Bereavement Leave Amendment

Create this for my brand

TAThe AI in Business Podcast

Governing Enterprise AI: Balancing Risk, ROI, and Performance

Create this for my brand

TUThe UltraWellness Center

Mel Robbins on Making Healthy Changes Stick

Create this for my brand

The Skimm

This microplastics news is scary

Create this for my brand

Barracuda

What is an AI worm?

Create this for my brand

GGallup

Record Lows Say Congressional Incumbents Deserve Reelection

Create this for my brand

The Seattle Times

Wednesday Morning Brief: Almost time to 'fall back' (even if you hate it!)

Create this for my brand